Table 2.

Patients with AML entered into the CDDO phase 1 clinical trial

ID	FAB	Etiology	Cytogenetics	Dose level of RTA401 (CDDO), mg/m2 per h for 5 d	Prior no. of Rx
301	UNK	AHD	46, XY, t(1;22)(p36.3;q11.2), del(5)(q13q33)[13], 48, XY, del(5)(q13q33),+22, +mar[7]	0.6	1
302	UNK	De novo	46, XY, t(1;4)(p32;p16)[1], 46, XY[19]	1.2	3
303	RAEB-T	2°	45, X,−Y, der(3)ins(22;9)(q11.2;q34q34)t(3;22)(p23;q11.2), der(9)ins(22;9), der(22)t(3;22)[1], 44, X, −Y, der(3)ins(22;9)(q11.2;q34q34)t(3;22)(p23;q11.2), der(9)ins(22;9), −18, der(22)t(3;22)[8], 46, XX[11]	2.4	2
304	UNK	AHD	46, XX[19]	4.8	1
305	M4	AHD	NA	9.6	3

All patients had a diagnosis of AML.

Rx indicates treatment; UKN, unknown; AHD, antecedent hematologic disease; 2°, secondary; and NA, not available.